Captopril and MK-421: stability on storage, distribution to the central nervous system, and onset of activity.
D000284:Administration, Oral; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D000959:Antihypertensive Agents / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D002216:Captopril / Q000378:metabolism*; D004151:Dipeptides / Q000378:metabolism*; D004355:Drug Stability; D004356:Drug Storage; D004656:Enalapril; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D011392:Proline / Q000031:analogs & derivatives*; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors; D014018:Tissue Distribution
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004151:Dipeptides; D004656:Enalapril; D011392:Proline; D002216:Captopril